Palatin Technologies, Inc. (AMEX: PTN)

PTN Technical Analysis

4

As on
31st Oct 2017 PTN Share Price closed @
0.75 and we RECOMMENDStrong Buy
for LONG-TERM with Stoploss of
0.47 &
Buy for SHORT-TERM with Stoploss of
0.62
we also expect STOCK to react on Following IMPORTANT LEVELS.

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. Its clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that is in Phase III clinical trials for the treatment of female sexual dysfunction. The companys drug development programs comprise PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase 1 clinical trial for the treatment of cardiovascular and pulmonary indications; melanocortin receptor-based compounds for treatment of obesity; and Melanocortin receptor-1 agonist peptides for treatment of dermatologic and inflammatory disease indications. Palatin Technologies, Inc. has research collaboration and license agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome. The company was founded in 1986 and is based in Cranbury, New Jersey.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors or delays in the content,
or for any actions taken in reliance thereon.
Your use of this website constitutes acceptance of our Terms Of Service